EXSERVAN

Drug MITSUBISHI TANABE PHARMA AMERICA, INC.
Total Payments
$23,156
Transactions
39
Doctors
33
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $11,056 29 29
2021 $12,100 10 6

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $22,760 20 98.3%
Food and Beverage $395.97 19 1.7%

Top Doctors Receiving Payments for EXSERVAN — Page 2

Doctor Specialty Location Total Records
, MD Neurology Pomona, CA $16.84 1
, PA Physician Assistant Pomona, CA $16.84 1
, MD Neurology Arcadia, CA $16.47 1
, MD Neurology Los Angeles, CA $14.61 1
, M.D Neurology Apple Valley, CA $14.50 1
, M.D Neurology Whittier, CA $14.26 1
, M.D Neurology Whittier, CA $14.25 1
, D.O Neurology Upland, CA $14.21 1

About EXSERVAN

EXSERVAN is a drug associated with $23,156 in payments to 33 healthcare providers, recorded across 39 transactions in the CMS Open Payments database. The primary manufacturer is MITSUBISHI TANABE PHARMA AMERICA, INC..

Payment data is available from 2021 to 2023. In 2023, $11,056 was paid across 29 transactions to 29 doctors.

The most common payment nature for EXSERVAN is "Consulting Fee" ($22,760, 98.3% of total).